查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2000960

牛結核病診斷市場：2026-2032年全球市場預測（依檢測方法、產品類型、檢體類型和最終用戶分類）

Bovine Tuberculosis Diagnosis Market by Test Type, Product, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，牛結核病診斷市場價值將達到 9.608 億美元，到 2026 年將成長至 10.417 億美元，到 2032 年將達到 17.4816 億美元，年複合成長率為 8.92%。

主要市場統計數據
基準年 2025 9.608億美元
預計年份：2026年 1,041,700,000 美元
預測年份 2032 1,748,160,000 美元
複合年成長率 (%) 8.92%

對影響全球牛結核病診斷的不斷變化的科學、操作和政策因素進行了簡明扼要且權威的概述。

牛結核病仍是動物健康領域持續存在的挑戰，對畜牧業生產力、貿易誠信和公共衛生等關鍵環節造成重大影響。診斷牛分枝桿菌感染疾病需要利用多種免疫學和分子生物學平台進行精確檢測，檢查室在實施篩檢和確診檢測流程時必須權衡靈敏度、特異性和操作可行性。診斷策略是監測計畫、監管決策和市場進入通訊協定的基礎，凸顯了穩健且可互通的偵測框架的重要性。

技術進步、綜合監測框架和採購韌性如何從根本上改變全球牛結核病診斷生態系統。

牛結核病的診斷格局正在經歷一場變革，這主要得益於技術創新、跨部門合作以及對綜合監測的重新重視。免疫檢測的改進，例如更具選擇性的抗原和多重檢測平台，在不犧牲靈敏度的前提下提高了特異性，從而減少了已接種疫苗人群和交叉反應人群中的假陽性結果。同時，核酸擴增方法也變得更加便捷快速，使得確診檢測能夠縮短結果報告時間，並提高了菌株層面的流行病學溯源性。

了解美國在 2025 年實施的關稅措施對診斷試劑供應造成的多方面影響，這些影響將波及供應鏈、採購和驗證。

美國2025年實施的一系列關稅措施的累積影響，為診斷供應鏈、採購計畫和競爭定位帶來了新的考量。關稅帶來的成本壓力直接影響進口診斷設備和關鍵試劑，進而影響採購時機、庫存策略以及國內生產和區域採購的相對吸引力。檢查室和政府採購負責人在選擇常規檢測和確診檢測平台時，正在重新評估總到岸成本和物流前置作業時間。

基於全面細分的診斷見解，揭示了每種測試方式、產品系列以及不同最終用戶的營運重點的不同要求。

精準的市場區隔觀點闡明如何根據偵測類型、產品類型和最終用戶環境來客製化診斷策略。基於檢測類型的市場分析區分了免疫學篩檢方法（例如尾部皮膚試驗，包括比較性皮內子宮頸試驗和單次皮內子宮頸試驗）、血清學檢測（例如酶聯免疫吸附試驗 (ELISA)）、以γ干擾素檢測為代表的細胞反應測量以及PCR分子確認。每種檢測類別都具有不同的診斷特徵。皮內試驗因其易用性而被定位為現場篩檢的一線篩檢；基於ELISA的檢測方法可提供擴充性的血清學監測；γ干擾素檢測可透過測量細胞免疫力在某些情況下實現早期檢測；而PCR則可在病原體層面進行明確診斷並鑑定菌株。

基礎設施、法規結構和農業系統的區域差異如何影響全球市場的診斷重點和可操作的實施策略？

區域差異顯著影響診斷途徑、監管預期和供應鏈結構。在美洲，完善的監測系統和大規模的商業牲畜群使得現場篩檢和實驗室確診檢測得以常規進行。該地區的實驗室通常優先採用高通量ELISA平台和基於PCR的確診方法進行追蹤，同時也要兼顧偏遠產區快速照護現場（ POC）的需求。貿易趨勢和跨境疾病控制框架進一步促進了診斷標準的協調統一和合作監測舉措的發展。

透過檢驗品質、綜合支援服務、法規遵循和強大的製造系統來建立競爭優勢的商業性和技術策略。

各公司的主要發展趨勢集中在儀器創新、試劑盒組成、試劑品質和服務交付等方面的能力提升。領先的診斷公司和專業製造商加大對檢測特異性、穩健的供應鏈和監管文件的投入，從而更好地滿足買家對檢驗且切實可行的解決方案的期望。儀器製造商和試劑供應商之間的夥伴關係，透過捆綁產品增強相容性、簡化檢驗並減輕整合負擔，從而加速檢查室部署。

為診斷公司和組織的相關人員提供以行動為導向、優先考慮和具有戰略意義的干涉措施，以增強檢驗、交付韌性、數位整合和「同一健康」合作。

產業領導者應優先考慮一系列合作舉措，以提高診斷可靠性、供應連續性和市場應對力。首先，加快在多種檢體基質和目標族群中的檢驗，將降低在不同現場環境中部署檢測的不確定性，並有助於獲得監管部門的核准。投資於跨機構能力測試和第三方檢驗研究，將增強採購機構的信心，並支持統一的監測通訊協定。

採用透明且可重複的混合方法研究途徑，結合技術文獻、與關鍵相關人員的訪談和檢查室觀察，以檢驗診斷結果。

本分析的研究結合了定性訪談和現場觀察，並對同行評審文章、監管指導文件和技術標準進行了系統性回顧。二手文獻提供了檢測方法的性能特徵、監管路徑和以往監測通訊協定的背景信息，而與實驗室管理人員、獸醫和採購專家的系列訪談則提供了關於推廣應用障礙和實際工作流程的運營觀點。

簡要概述強調了建立互通性、檢驗且具有彈性的診斷系統以支持監測、貿易和公共衛生目標的必要性。

有效管理牛結核病診斷需要綜合觀點技術能力、操作限制和政策目標。診斷方法的選擇並非純粹的技術問題，而是與監管環境、貿易考慮以及最終用戶實施和維護檢測流程的能力密切相關。不斷發展的檢測技術、不斷變化的採購環境以及區域差異凸顯了製定適應性策略的必要性，這些策略應優先考慮檢驗、韌性和互通性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：牛結核病診斷市場－檢測類型

  • 檢查尾部皮膚褶皺
    • 比較性子宮頸皮內研究
    • 單子宮頸皮內試驗
  • ELISA
  • γ干擾素檢測法
  • PCR

第9章：牛結核病診斷市場：依產品分類

  • 裝置
    • ELISA 閱讀器
    • PCR裝置
  • 成套工具
    • 尾部皮膚褶皺檢測套組
    • ELISA試劑盒
    • γ干擾素測量試劑盒
    • PCR試劑盒
  • 試劑
    • 抗原
    • 酵素
    • 引子和探針

第10章：依檢體類型分類的牛結核病診斷市場

  • 血液檢體
    • 全血
    • 血清
    • 電漿
  • 牛奶樣品
  • 組織和病變樣本
    • 淋巴結組織
    • 器官和病變組織
  • 呼吸道和拭子檢體
    • 鼻拭子
    • 支氣管肺泡灌洗液

第11章：牛結核病診斷市場：依最終用戶分類

  • 診斷檢測實驗室
  • 政府機構
  • 研究機構
  • 動物醫院

第12章：牛結核病診斷市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：牛結核病診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章牛結核病診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國牛結核病診斷市場

第16章：中國牛結核病診斷市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AsureQuality Australia Pty Ltd.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Bionote USA Inc.
  • Boehringer Ingelheim GmbH
  • CZ Vaccines SAU
  • Enfer Group
  • Enfer Group
  • F. Hoffmann-La Roche AG
  • IDEXX Laboratories, Inc.
  • Lionex GmbH
  • Pall Corporation
  • PBD Biotech Ltd.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Zoetis Inc.
Product Code: MRR-0D217D5AD942

The Bovine Tuberculosis Diagnosis Market was valued at USD 960.80 million in 2025 and is projected to grow to USD 1,041.70 million in 2026, with a CAGR of 8.92%, reaching USD 1,748.16 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 960.80 million
Estimated Year [2026] USD 1,041.70 million
Forecast Year [2032] USD 1,748.16 million
CAGR (%) 8.92%

A concise yet authoritative orientation to the evolving scientific, operational, and policy drivers shaping bovine tuberculosis diagnostic decision-making globally

Bovine tuberculosis remains a persistent animal health challenge with significant implications for livestock productivity, trade integrity, and public health interfaces. The diagnosis of Mycobacterium bovis infections demands precision across a range of immunological and molecular platforms, and laboratories must balance sensitivity, specificity, and operational feasibility when implementing screening and confirmatory workflows. Diagnostic strategies underpin surveillance programs, regulatory decisions, and market access protocols, which elevates the importance of robust, interoperable testing frameworks.

Recent years have seen a convergence of technological maturation and operational pressures that reshape how stakeholders evaluate diagnostic performance. Advances in immunoassays, nucleic acid amplification techniques, and laboratory automation have altered testing paradigms, while policy shifts and supply chain volatility force laboratories and procurement teams to reassess vendor relationships and contingency plans. As a result, decision-makers require balanced, evidence-based insights to align diagnostic adoption with regulatory compliance, herd health objectives, and cost-effective laboratory operations.

This executive summary synthesizes contemporary diagnostic dynamics, examines the regulatory and trade environment influences, and offers segmentation-based insights to inform procurement, laboratory deployment, and research prioritization. The emphasis is on actionable analysis that supports rapid, defensible choices across testing modalities and end-user settings, while maintaining a clear view of regional operational heterogeneity and strategic vendor considerations.

How technological advances, integrated surveillance frameworks, and procurement resilience are fundamentally reshaping bovine tuberculosis diagnostic ecosystems worldwide

Diagnostic landscapes for bovine tuberculosis are undergoing transformative shifts driven by technological innovation, cross-sector collaboration, and a renewed focus on integrated surveillance. Immunoassay refinements such as more selective antigens and multiplexed platforms are improving specificity without sacrificing sensitivity, thereby reducing false positives in vaccinated or cross-reactive populations. In parallel, nucleic acid amplification methods have become more accessible and faster, enabling confirmatory testing with reduced turnaround times and enhanced traceability of strain-level epidemiology.

Operationally, laboratories are embracing digital workflows and automation to scale throughput while preserving quality control. Connectivity between field sampling, laboratory information management systems, and national surveillance databases is improving real-time situational awareness and facilitating targeted interventions. Moreover, the One Health paradigm is strengthening collaborative ties between veterinary services, public health authorities, and environmental agencies, prompting cross-disciplinary data sharing and harmonized diagnostic standards.

Market dynamics are also shifting as stakeholders prioritize resilience. Procurement strategies increasingly emphasize supplier diversification, validated secondary sourcing, and inventory management to mitigate disruption risks. These shifts are reinforced by evolving regulatory expectations that require clearer evidentiary pathways for novel assays and streamlined validation protocols for emergency deployment. Taken together, these trends are accelerating the modernization of diagnostic ecosystems and shaping the priorities of laboratories, regulators, and industry partners.

Understanding the multifaceted supply chain, procurement, and validation consequences arising from United States tariff actions enacted during 2025 that affect diagnostic availability

The cumulative effects of United States tariff measures implemented in 2025 have introduced new considerations across diagnostic supply chains, procurement planning, and competitive positioning. Tariff-driven cost pressures have a direct impact on imported diagnostic instruments and critical reagents, which in turn influence procurement timing, inventory strategies, and the relative attractiveness of domestic manufacturing or regional sourcing. Laboratories and government purchasers are reassessing total landed costs and logistical lead times when selecting platforms for routine and confirmatory testing.

Beyond unit cost impacts, tariffs have catalyzed strategic shifts among suppliers and buyers. Vendors that previously concentrated manufacturing in single geographies are accelerating nearshoring and diversification initiatives to preserve market access and protect margin structures. This reorientation has implications for product availability timelines, after-sales support models, and validation cycles, since newly localized production lines often require regulatory re-submissions or additional quality audits. Consequently, diagnostic adopters must factor in not only price variance but also service continuity and validation overheads when selecting platforms.

For public health and veterinary authorities, tariffs have emphasized the importance of collaborative procurement frameworks, pooled purchasing, and public-private partnerships that can leverage scale to absorb trade-related cost shocks. At the same time, research and development priorities are adapting: investments in reagent substitutes, assay reformulation, and interoperability of legacy platforms are being prioritized to maintain testing capacity under disrupted import conditions. These cumulative dynamics underscore the need for proactive supply chain risk management and collaborative policy responses to safeguard diagnostic readiness.

Comprehensive segmentation-driven diagnostic insights that reveal distinct requirements across test modalities, product families, and diverse end-user operational priorities

A nuanced segmentation lens clarifies how diagnostic strategies must be tailored across test types, product categories, and end-user settings. Based on Test Type, market analysis differentiates between immunological screening such as Caudal Fold Test modalities with their Comparative Intradermal Cervical and Single Intradermal Cervical variants, serological assays like ELISA, cellular response measures exemplified by Gamma Interferon Assay, and molecular confirmation via PCR. Each test category offers a distinct mix of diagnostic attributes: the intradermal tests remain frontline for field screening with operational simplicity, ELISA-based tests provide scalable serological surveillance, Gamma Interferon assays deliver earlier detection in some cases through cell-mediated immunity measures, and PCR affords pathogen-level confirmation and strain characterization.

Based on Product, diagnostic ecosystems encompass Instruments, Kits, and Reagents that together form end-to-end testing workflows. Instruments range from ELISA readers to PCR machines, whose throughput, automation, and data integration capabilities influence laboratory efficiency and cost per test. Kits include tailored solutions for Caudal Fold Test Kits, ELISA Kits, Gamma Interferon Assay Kits, and PCR Kits, each requiring validation for specific host populations and use-cases. Reagents cover Antigens, Enzymes, and Primers and Probes, with primers and probes further disaggregated into primer and probe components critical for molecular specificity. Quality, cold-chain robustness, and batch-to-batch consistency of these inputs directly affect diagnostic reliability and regulatory acceptability.

Based on End User, diagnostic needs diverge across Diagnostic Laboratories, Government Agencies, Research Institutes, and Veterinary Hospitals. Diagnostic laboratories prioritize throughput, standardized quality control procedures, and regulatory compliance. Government agencies focus on surveillance integration, export-import implications, and outbreak response readiness. Research institutes emphasize assay development, validation, and epidemiological analytics, while veterinary hospitals require practical, rapid-result diagnostics that support clinical decision-making at the herd or individual animal level. Understanding these segment-specific priorities is essential to align product development, service models, and distribution strategies with real-world user constraints and expectations.

How distinct regional infrastructures, regulatory frameworks, and agricultural systems drive divergent diagnostic priorities and practical deployment strategies across global markets

Regional heterogeneity significantly shapes diagnostic adoption pathways, regulatory expectations, and supply chain architectures. In the Americas, well-established surveillance infrastructures and large commercial herds support routine deployment of both field screening tests and laboratory-based confirmatory assays. Laboratories in this region often prioritize high-throughput ELISA platforms and PCR confirmation for trace-back investigations, while also balancing the need for rapid point-of-care screening in remote production areas. Trade dynamics and cross-border disease management frameworks further incentivize harmonized diagnostic standards and collaborative surveillance initiatives.

Within Europe, Middle East & Africa, the diagnostic landscape is highly heterogeneous, encompassing regions with sophisticated laboratory networks alongside areas facing resource constraints. Regulatory harmonization efforts across parts of Europe provide a framework for standardized assay validation and mutual recognition, whereas in some Middle Eastern and African contexts, priorities include strengthening cold-chain logistics, local capacity building, and scalable, field-appropriate tests. Donor-supported programs and regional veterinary networks play a critical role in enabling access to diagnostics, while also creating opportunities for technology transfer and localized manufacturing to reduce dependency on long supply chains.

Asia-Pacific exhibits rapid modernization of diagnostic capabilities coupled with significant variation across national systems. Large-scale agricultural producers and research centers are investing in molecular confirmation and integrated data systems, yet smallholder-dominated regions emphasize low-cost, easy-to-use screening tests and decentralized sampling strategies. Cross-border trade, zoonotic risk awareness, and investments in laboratory accreditation are driving uptake of higher-sensitivity assays in some markets, while others adopt hybrid models that combine field screening with centralized confirmatory testing. Recognizing these regional contrasts is essential when designing distribution strategies, regulatory engagement plans, and capacity-building initiatives.

Commercial and technical strategies that define competitive advantage through assay quality, integrated support services, regulatory enablement, and resilient manufacturing footprints

Key company dynamics center on capabilities that span instrument innovation, kit formulation, reagent quality, and service delivery. Leading diagnostic firms and specialized manufacturers that invest in assay specificity, robust supply chains, and regulatory dossier development are better positioned to meet buyer expectations for validated, deployable solutions. Partnerships between instrument makers and reagent suppliers enhance compatibility and accelerate laboratory adoption through bundled offerings that simplify validation and reduce integration overhead.

Competitive differentiation increasingly relies on post-market support, training services, and digital enablement that streamline laboratory workflows. Companies offering laboratory information management integrations, remote calibration, and quality assurance programs add measurable value for large diagnostic networks and government programs. At the same time, upstream investments in assay research-particularly in antigen refinement and primer/probe design-are critical to maintaining clinical performance amid cross-reactivity challenges and evolving pathogen epidemiology.

Strategic moves such as regional manufacturing expansions, collaborations with academic groups for validation studies, and flexible commercial models that include reagent rental or reagent-as-a-service can materially influence market access. Firms that proactively address supply chain resilience, offer validated secondary sourcing, and provide clear regulatory support pathways for customers will be best placed to secure long-term institutional contracts and to support emergency response scenarios.

Practical and prioritized strategic interventions for diagnostic companies and institutional stakeholders to enhance validation, supply resilience, digital integration, and One Health collaboration

Industry leaders should prioritize a coordinated set of actions to strengthen diagnostic reliability, supply continuity, and market responsiveness. First, accelerating validation efforts across multiple matrices and host populations will reduce uncertainty when deploying assays in heterogeneous field conditions and facilitate regulatory acceptance. Investing in cross-laboratory proficiency testing and third-party validation studies builds confidence among procurement agencies and supports harmonized surveillance protocols.

Second, diversifying supply chains and expanding regional manufacturing or distribution hubs mitigates tariff and logistics risk while reducing lead times for critical instruments and reagents. Strategic partnerships with local manufacturers and contract development organizations can preserve product quality while improving responsiveness to sudden demand surges. Third, embedding digital connectivity into diagnostic workflows-through automated readers, cloud-based reporting, and interoperable LIMS-improves traceability, speed of reporting, and outbreak analytics, thereby delivering public health value beyond individual test results.

Fourth, companies should adopt flexible commercial models and invest in training programs for end users to enhance adoption and ensure correct test interpretation. Finally, alignment with One Health stakeholders through data-sharing initiatives and joint training fosters integrated responses to zoonotic risk and elevates the role of diagnostic evidence in policy-making and trade negotiations. Executing these recommendations will strengthen operational readiness and create competitive differentiation in a dynamic diagnostic environment.

A transparent and reproducible mixed-methods research approach that integrates technical literature, primary stakeholder interviews, and laboratory observations to validate diagnostic insights

The research underpinning this analysis combined structured reviews of peer-reviewed publications, regulatory guidance documents, and technical standards with primary qualitative interviews and facility-level observations. Secondary literature provided context on assay performance characteristics, regulatory pathways, and historical surveillance protocols, while an array of expert interviews with laboratory directors, veterinarians, and procurement specialists offered operational perspectives on adoption barriers and real-world workflows.

Primary data collection included semi-structured interviews to explore validation requirements, supply chain experiences, and post-market support expectations. Field observations in diagnostic laboratories and veterinary clinics informed assessments of throughput constraints, cold-chain practices, and staff training needs. Triangulation across these inputs ensured that conclusions reflect both technical performance metrics and practical operational realities. Quality control measures included independent review of technical summaries by subject-matter experts and cross-validation of key findings against public regulatory guidance and published assay evaluations.

The methodology emphasized transparency and reproducibility by documenting data sources, interview guides, and validation steps. Stakeholder engagement prioritized representativeness across laboratory types and geographical regions to capture heterogeneity in needs and capabilities. Where applicable, sensitivity checks and scenario analyses were used to test the robustness of recommendations under different operational and trade conditions.

A concise synthesis highlighting the imperative for interoperable, validated, and resilient diagnostic systems that support surveillance, trade, and public health objectives

Effective management of bovine tuberculosis diagnostics requires an integrated perspective that aligns technological capabilities with operational constraints and policy objectives. Diagnostic selection is not a purely technical choice; it intersects with regulatory frameworks, trade considerations, and the capacity of end users to implement and sustain testing workflows. The combined effect of evolving assay technologies, shifting procurement landscapes, and regional heterogeneity underscores the need for adaptive strategies that prioritize validation, resilience, and interoperability.

Decision-makers should focus on building modular diagnostic ecosystems where screening, confirmation, and data management components are interoperable and supported by clear validation evidence and supply chain contingencies. Cross-sector collaboration and investment in local capacity can reduce vulnerabilities and enable faster, evidence-based responses to outbreaks. Ultimately, strengthening diagnostic systems for bovine tuberculosis yields benefits that extend into public health, trade confidence, and animal productivity, making it a high-priority area for coordinated investment and policy attention.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bovine Tuberculosis Diagnosis Market, by Test Type

  • 8.1. Caudal Fold Test
    • 8.1.1. Comparative Intradermal Cervical Test
    • 8.1.2. Single Intradermal Cervical Test
  • 8.2. Elisa
  • 8.3. Gamma Interferon Assay
  • 8.4. PCR

9. Bovine Tuberculosis Diagnosis Market, by Product

  • 9.1. Instruments
    • 9.1.1. ELISA Readers
    • 9.1.2. PCR Machines
  • 9.2. Kits
    • 9.2.1. Caudal Fold Test Kits
    • 9.2.2. Elisa Kits
    • 9.2.3. Gamma Interferon Assay Kits
    • 9.2.4. PCR Kits
  • 9.3. Reagents
    • 9.3.1. Antigens
    • 9.3.2. Enzymes
    • 9.3.3. Primers And Probes

10. Bovine Tuberculosis Diagnosis Market, by Sample Type

  • 10.1. Blood Samples
    • 10.1.1. Whole Blood
    • 10.1.2. Serum
    • 10.1.3. Plasma
  • 10.2. Milk Samples
  • 10.3. Tissue And Lesion Samples
    • 10.3.1. Lymph Node Tissue
    • 10.3.2. Organ And Lesion Tissue
  • 10.4. Respiratory And Swab Samples
    • 10.4.1. Nasal Swabs
    • 10.4.2. Bronchoalveolar Lavage Fluid

11. Bovine Tuberculosis Diagnosis Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Government Agencies
  • 11.3. Research Institutes
  • 11.4. Veterinary Hospitals

12. Bovine Tuberculosis Diagnosis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bovine Tuberculosis Diagnosis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bovine Tuberculosis Diagnosis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Bovine Tuberculosis Diagnosis Market

16. China Bovine Tuberculosis Diagnosis Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AsureQuality Australia Pty Ltd.
  • 17.6. Becton, Dickinson and Company
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. BioMerieux S.A.
  • 17.9. Bionote USA Inc.
  • 17.10. Boehringer Ingelheim GmbH
  • 17.11. CZ Vaccines S.A.U.
  • 17.12. Enfer Group
  • 17.13. Enfer Group
  • 17.14. F. Hoffmann-La Roche AG
  • 17.15. IDEXX Laboratories, Inc.
  • 17.16. Lionex GmbH
  • 17.17. Pall Corporation
  • 17.18. PBD Biotech Ltd.
  • 17.19. Takara Bio Inc.
  • 17.20. Thermo Fisher Scientific Inc.
  • 17.21. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COMPARATIVE INTRADERMAL CERVICAL TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COMPARATIVE INTRADERMAL CERVICAL TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COMPARATIVE INTRADERMAL CERVICAL TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SINGLE INTRADERMAL CERVICAL TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SINGLE INTRADERMAL CERVICAL TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SINGLE INTRADERMAL CERVICAL TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA READERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA READERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA READERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GAMMA INTERFERON ASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ANTIGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ANTIGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ANTIGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRIMERS AND PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY MILK SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY MILK SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY MILK SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY LYMPH NODE TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY LYMPH NODE TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY LYMPH NODE TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ORGAN AND LESION TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ORGAN AND LESION TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY ORGAN AND LESION TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY NASAL SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY NASAL SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY NASAL SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 225. GCC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 226. GCC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. GCC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 232. GCC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 233. GCC BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. G7 BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. G7 BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. G7 BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 261. G7 BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 262. G7 BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 263. G7 BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 265. G7 BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. G7 BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 267. G7 BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 268. G7 BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 269. G7 BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. NATO BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. NATO BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. NATO BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 273. NATO BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 274. NATO BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 275. NATO BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 276. NATO BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 277. NATO BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. NATO BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 279. NATO BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 280. NATO BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 281. NATO BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY BLOOD SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TISSUE AND LESION SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY RESPIRATORY AND SWAB SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY CAUDAL FOLD TEST, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA BOVINE TUBERCULOSIS DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)